1. Home
  2. HWC vs BLTE Comparison

HWC vs BLTE Comparison

Compare HWC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hancock Whitney Corporation

HWC

Hancock Whitney Corporation

HOLD

Current Price

$74.84

Market Cap

6.1B

Sector

Finance

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$191.29

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HWC
BLTE
Founded
1883
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1B
6.0B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
HWC
BLTE
Price
$74.84
$191.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
7
Target Price
$77.67
$198.00
AVG Volume (30 Days)
565.1K
177.4K
Earning Date
04-21-2026
05-08-2026
Dividend Yield
3.00%
N/A
EPS Growth
7.39
N/A
EPS
2.12
N/A
Revenue
N/A
N/A
Revenue This Year
$11.59
N/A
Revenue Next Year
$4.42
$492.11
P/E Ratio
$35.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$54.05
$65.00
52 Week High
$80.13
$200.00

Technical Indicators

Market Signals
Indicator
HWC
BLTE
Relative Strength Index (RSI) 45.13 73.31
Support Level $74.75 $147.34
Resistance Level $75.91 $196.14
Average True Range (ATR) 1.43 7.85
MACD -0.12 3.26
Stochastic Oscillator 34.91 93.58

Price Performance

Historical Comparison
HWC
BLTE

About HWC Hancock Whitney Corporation

Hancock Whitney Corp operates bank offices and financial centers. The company offers a range of traditional and online banking services to commercial, small business, and retail customers, providing a variety of transaction and savings deposit products, treasury management services, secured and unsecured loan products (including revolving credit facilities), letters of credit, and similar financial guarantees. The Bank provides trust and investment management services to retirement plans, corporations, and individuals and provides its customers access to investment advisory and brokerage products.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: